OncoResponse Announces Initiation of Phase 1 Trial of OR2805 – Human Monoclonal Antibody Derived from Elite Responder to Cancer Immunotherapy – in Patients with Advanced Cancer

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of elite cancer responders, today announced initiation of a Phase I/II study of OR2805 in patients with advanced cancer.